Regentis Biomaterials: Funding, Investors & Team (Oct 2026)
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.
Regentis Biomaterials has raised $6.5M across 1 funding round on record, the most recent an undisclosed round of $6.5M announced in Jun 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Regentis Biomaterials Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Regentis Biomaterials Funding Rounds
Regentis Biomaterials Founders and Leadership Team
No contact details are on record for this team yet.
Regentis Biomaterials Funding Compared to Other Biotechnology Startups
Regentis Biomaterials' latest round of $6.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Regentis Biomaterials in Biotechnology and Or Akiva
Companies Similar to Regentis Biomaterials
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and…
Regentis Biomaterials Funding FAQs
What does Regentis Biomaterials do?
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.
How much funding has Regentis Biomaterials raised?
Regentis Biomaterials has raised $6.5M across 1 round on record. The most recent is an undisclosed round of $6.5M announced in Jun 2026.
When did Regentis Biomaterials last raise funding?
Regentis Biomaterials' most recent funding round on record is an undisclosed round of $6.5M, announced in Jun 2026.
Who founded Regentis Biomaterials?
FundedIQ lists Keith Valentine (Founder) at Regentis Biomaterials.
Where is Regentis Biomaterials headquartered?
Regentis Biomaterials is based in Or Akiva, Hefa, Israel.
How many employees does Regentis Biomaterials have?
Regentis Biomaterials is in the 11-50 employee band.
How does Regentis Biomaterials' funding compare to other Biotechnology startups?
Regentis Biomaterials' latest round of $6.5M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Regentis Biomaterials Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Regentis Biomaterials is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.